Please use this identifier to cite or link to this item:
http://ri.uaemex.mx/handle20.500.11799/68858| Title: | First report of multiple anthelmintic resistance in goat farm in Cuba | Keywords: | Haemonchus spp;anthelmintics;multiple anthelmintic resistance;goats;info:eu-repo/classification/cti/4 | Publisher: | GRUYTER | Description: | This study determined the efficacies of four classes of anthelmintics (AH) in a goat flock where anthelmintic resistance (AR) to ivermectin was suspected. We selected and randomly distributed 105 animals with >500 eggs per gram of feces into seven groups of 15 animals: an untreated con- trol group and groups treated with ivermectin, eprinomectin, albendazole sulfoxide, albendazole, levamisole, and closantel. The goats were individually weighed and treated with the recommended dose. Fecal samples were collected 14 days post-treatment to determine the fecal egg counts and for a fecal egg count reduction test (FECRT). Coprocultures were also performed for identifying any resistant genera. A molecular assay (polymerase chain reaction, PCR) was used to confirm benzimidazole resistance. The FECRTs for the ivermectin, eprinomectin, albendazole sulfoxide, and albendazole treatments were <90 %, indicating multiple anthelmintic resistance, all in Haemonchus spp. Levamisole had a FECRT confidence interval <90 %, indicating a moderate level of AR. The PCR detected the ß-tubulin alleles responsible for benzimidazole resistance, confirming AR. This study is the first monospecific report of AR in goats in Cuba, with a total failure of macrocyclic lac- tones anthelmintic class. The project was funded by the Cuban Ministry of Agriculture (Pro- ject No. P131LH001-0072). |
URI: | http://ri.uaemex.mx/handle20.500.11799/68858 | Other Identifiers: | http://hdl.handle.net/20.500.11799/68858 | Rights: | info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0 |
| Appears in Collections: | Producción |
Show full item record
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.